California Public Employees Retirement System Trims Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

California Public Employees Retirement System decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 10.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,948 shares of the company's stock after selling 10,908 shares during the period. California Public Employees Retirement System owned 0.11% of CRISPR Therapeutics worth $3,777,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics during the fourth quarter valued at $39,000. Western Pacific Wealth Management LP increased its holdings in shares of CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after acquiring an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter worth about $40,000. Spire Wealth Management grew its position in CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after purchasing an additional 1,482 shares during the last quarter. Finally, MCF Advisors LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth approximately $80,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded up $0.25 during trading on Monday, reaching $39.55. 290,206 shares of the stock traded hands, compared to its average volume of 2,223,401. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of -9.05 and a beta of 1.85. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $67.88. The business has a fifty day simple moving average of $41.14 and a two-hundred day simple moving average of $44.01.

Remove Ads

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at $350,516.46. This represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,381 shares of company stock valued at $1,608,243. Insiders own 4.10% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on CRSP shares. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research report on Friday, March 21st. Chardan Capital cut their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and raised their target price for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.